Merck invests $1B in Seattle Genetics to develop cancer therapy

Merck stated Sept. 14 it will get a $1 billion stake in Seattle Genetics, a Bothell, Wash.-based drugmaker focused on cancer treatments..

More articles on drug store: Trump indications brand-new officer order targeted at reducing drug pricesBaptist Health opens 2 new retail pharmaciesAstraZeneca resumes UK vaccine trial after stopping due to individuals unfavorable response.

The two drugmakers will co-develop Seattle Genetics ladiratuzumab vedotin, an investigational antibody drug in clinical trials for breast cancer and other solid tumors..

Maia Anderson –
Monday, September 14th, 2020
Print|Email.

Under the deal, Seattle Genetics is qualified for progress-dependent payments of approximately $2.6 billion from Merck..

Seattle Genetics likewise gave Merck an unique license to advertise Tuksya, its drug designed to treat HER2-positive cancers. Under that offer, Seattle Genetics will get $125 million from Merck and is qualified for progress-dependent payments of as much as $65 million..

They will likewise check the drug in mix with Mercks cancer immunotherapy Keytruda..

Check out the full news release here..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.